Shionogi To File HIV Integrase Inhibitor Dolutegravir In U.S. And Europe By Year End
This article was originally published in PharmAsia News
Shionogi Pharmaceuticals announced Oct. 4 it plans to file an application for new HIV integrase inhibitor dolutegravir (development code S-349572) in the United States and Europe in 2012.
You may also be interested in...
Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
After a stunning first efficacy readout for its mRNA-based vaccine, the biotech company's leaders in Europe talk about their rapid commercial and manufacturing scale-up.